A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
2025-01-05
عنوان الدراسة
A Phase 2/3 Randomized, Multicenter Study of Osivelotor Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease
داعم الدراسة
Global Blood Therapeutics Inc, a wholly owned subsidiary of Pfizer.
دواء الدراسة
Osivelotor
رقم بروتوكول الدراسة
C5351004 (GBT021601)
حالة الدراسة
Ongoing
موقع الدراسة
1. National Guard Health Affairs - Riyadh 2.Prince Mohammed bin Nasser Hospital - Jazan 3. King Saud University Medical city -Riyadh
مرحلة الدراسة
2/3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.